Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report)'s stock price rose 11% during mid-day trading on Wednesday . The stock traded as high as $10.68 and last traded at $11.05. Approximately 181,196 shares changed hands during trading, a decline of 78% from the average daily volume of 816,193 shares. The stock had previously closed at $9.95.
Analysts Set New Price Targets
EYPT has been the subject of several research analyst reports. Chardan Capital lowered their price target on shares of Eyepoint Pharmaceuticals from $33.00 to $27.00 and set a "buy" rating for the company in a report on Thursday, May 8th. Wall Street Zen upgraded shares of Eyepoint Pharmaceuticals to a "sell" rating in a report on Friday, March 14th. Mizuho lowered their price target on shares of Eyepoint Pharmaceuticals from $30.00 to $26.00 and set an "outperform" rating for the company in a report on Friday, May 16th. HC Wainwright reiterated a "buy" rating and set a $22.00 price target on shares of Eyepoint Pharmaceuticals in a report on Thursday, May 29th. Finally, Royal Bank Of Canada initiated coverage on shares of Eyepoint Pharmaceuticals in a report on Tuesday, June 17th. They set an "outperform" rating and a $28.00 price target for the company. One investment analyst has rated the stock with a sell rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $25.67.
Read Our Latest Report on Eyepoint Pharmaceuticals
Eyepoint Pharmaceuticals Price Performance
The firm has a market capitalization of $712.87 million, a price-to-earnings ratio of -4.30 and a beta of 1.67. The stock has a fifty day moving average of $8.01 and a two-hundred day moving average of $7.14.
Eyepoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported ($0.65) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.65). Eyepoint Pharmaceuticals had a negative return on equity of 54.27% and a negative net margin of 261.91%. The firm had revenue of $24.50 million during the quarter, compared to the consensus estimate of $8.84 million. On average, research analysts forecast that Eyepoint Pharmaceuticals, Inc. will post -2.13 EPS for the current year.
Institutional Trading of Eyepoint Pharmaceuticals
A number of large investors have recently bought and sold shares of the business. California State Teachers Retirement System grew its holdings in Eyepoint Pharmaceuticals by 3.8% during the 4th quarter. California State Teachers Retirement System now owns 48,614 shares of the company's stock worth $362,000 after acquiring an additional 1,797 shares during the period. Arizona State Retirement System grew its holdings in Eyepoint Pharmaceuticals by 12.7% during the 1st quarter. Arizona State Retirement System now owns 16,600 shares of the company's stock worth $90,000 after acquiring an additional 1,877 shares during the period. Legal & General Group Plc grew its holdings in Eyepoint Pharmaceuticals by 4.4% during the 4th quarter. Legal & General Group Plc now owns 46,263 shares of the company's stock worth $345,000 after acquiring an additional 1,932 shares during the period. Summit Investment Advisors Inc. grew its holdings in Eyepoint Pharmaceuticals by 39.6% during the 4th quarter. Summit Investment Advisors Inc. now owns 6,838 shares of the company's stock worth $51,000 after acquiring an additional 1,940 shares during the period. Finally, Invesco Ltd. grew its holdings in Eyepoint Pharmaceuticals by 16.1% during the 4th quarter. Invesco Ltd. now owns 15,657 shares of the company's stock worth $117,000 after acquiring an additional 2,177 shares during the period. 99.41% of the stock is currently owned by institutional investors and hedge funds.
Eyepoint Pharmaceuticals Company Profile
(
Get Free Report)
EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.
Further Reading
Before you consider Eyepoint Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eyepoint Pharmaceuticals wasn't on the list.
While Eyepoint Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
